Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
15 mai 2019 08h10 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
15 mai 2019 08h05 HE
|
Vaccinex, Inc.
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019 Enrollment in Phase 2 SIGNAL Huntington’s...
Vaccinex Announces Pricing of Initial Public Offering
09 août 2018 09h08 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
30 janv. 2018 11h14 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
08 janv. 2018 13h10 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
26 oct. 2017 10h23 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease)
24 avr. 2017 10h28 HE
|
Vaccinex, Inc.
- Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
06 oct. 2016 09h45 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to evaluate VX15/2503, an...
Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial
09 sept. 2016 09h45 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...
Vaccinex, Inc. Receives Orphan Drug Designation from U.S. FDA for its Lead Antibody Product Candidate, VX15, as a Potential Treatment for Huntington’s Disease
23 août 2016 10h15 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...